相关实验视频

Updated: Jan 10, 2026

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes

Published on: January 12, 2024

基于非自然双CRBN配体的新型PROTACs的设计,合成和生物评估

Kun Huang¹, Peng Luo¹, Cai-Hua Li¹

¹Sichuan Engineering Research Center for Biomimetic Synthesis of Natural Drugs, School of Life Science and Engineering, Southwest Jiaotong University, Chengdu, 610031, China.

European journal of medicinal chemistry

|November 28, 2025

概括

研究人员开发了新的非自然双脑 (CRBN) 配体,用于蛋白质解离向嵌合体 (PROTACs). 与传统免疫调节药物 (IMiDs) 相比,这些新配体提供了更好的特性和疗效,扩大了PROTAC的开发潜力.

科学领域:

药用化学医学化学
分子生物学分子生物学
药物发现药物发现药物发现

背景情况:

脑 (CRBN) 是CRL4 E3泛基因酶复合物的关键组成部分,是免疫调节药物 (IMiDs) 的目标.
CRBN被广泛用于针对性蛋白质降解的蛋白质溶解向奇美拉 (PROTAC) 设计.
现有的基于IMiD的CRBN配体具有局限性,包括致性风险和药物代谢和药物动力学 (DMPK) 特性差.

研究的目的:

开发CRBN配体的新型化学型,用于先进的PROTAC开发.
设计和评估使用非自然二基CRBN配体向BRD4和ALK的PROTAC.

主要方法:

新型非自然双CRBN配体的合成.
将这些配体纳入针对BRD4和ALK的PROTAC构造中.
对开发的PROTACs的蛋白质降解,抗增殖活性和新基质概况的评估.

主要成果:

新型二酸CRBN配体对非天然的疏水性氨基酸有很好的耐受性.
从这些配体中衍生出的PROTAC显示出强大的蛋白质降解和抗增殖活性,与基于IMiD的PROTAC相比或优于它.
非自然二PROTACs降低了IMiD相关新基质的降解,同时诱导了新型CRBN新基质的降解.

结论:

非天然的循环胺二化物作为多功能CRBN配体用于PROTAC设计跨越各种目标.
这些新型二化物CRBN配体扩大了CRBN招募PROTAC的化学空间和目标范围.
开发的连接体显示出创造向其他蛋白质的分子合剂的潜力.

关键词:

阿尔克 (ALK) 是一个这就是BRD4D.在C端的周期性伊米德二化物中.编号:CRBN 编号:CRBN 编号:CRBN 编号:CRBN 编号:CRBN 编号:CRBN 编号:CRBN 这就是PROTAC.

更多相关视频

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

Published on: July 25, 2013

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

相关概念视频

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...